KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Deferred Taxes (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of Deferred Taxes data on record, last reported at -$60.2 million in Q4 2025.

  • For Q4 2025, Deferred Taxes fell 45.2% year-over-year to -$60.2 million; the TTM value through Dec 2025 reached -$75.3 million, down 11.66%, while the annual FY2025 figure was -$75.3 million, 11.66% down from the prior year.
  • Deferred Taxes reached -$60.2 million in Q4 2025 per CRL's latest filing, down from $25.9 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $25.9 million in Q3 2025 and bottomed at -$60.2 million in Q4 2025.
  • Average Deferred Taxes over 5 years is -$12.7 million, with a median of -$11.6 million recorded in 2022.
  • Peak YoY movement for Deferred Taxes: soared 477.25% in 2021, then tumbled 1829.18% in 2025.
  • A 5-year view of Deferred Taxes shows it stood at -$10.2 million in 2021, then increased by 6.71% to -$9.6 million in 2022, then tumbled by 136.92% to -$22.7 million in 2023, then plummeted by 82.94% to -$41.4 million in 2024, then crashed by 45.2% to -$60.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Deferred Taxes were -$60.2 million in Q4 2025, $25.9 million in Q3 2025, and -$22.0 million in Q2 2025.